Paclitaxel (Ovarian Cancer) - Analysis and Forecasts to 2020

GlobalData, September 2011, Pages: 36

Paclitaxel (Ovarian Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, "Paclitaxel (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Paclitaxel sales forecasts for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU and Japan (seven major markets)
- Analysis and review of Paclitaxel including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Paclitaxel including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2002-2020 for Paclitaxel in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Paclitaxel, ovarian cancer, Taxol, first and second line treatment of advanced ovarian cancer, Bristol Myers Squibb, combination with carboplatin, standard treatment of advanced ovarian cancer, microtubule assembly, sales forecast, phase III/pipeline, competitors to paclitaxel EC145, Olaparib , Opaxio, Gemzar, Hycamtin, Hexalen, Doxil , Yondelis.

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Ovarian Cancer
2.2 Ovarian Cancer Market
2.3 Epidemiology
2.4 Etiology
2.4.1 Age
2.4.2 Inherited Gene Mutations
2.4.3 A Previous Cancer Diagnosis
2.4.4 Early Menstruation or Late Menopause
2.4.5 Family History of Ovarian Cancer
2.5 GlobalData Market Forecasts Report Guidance
3 Ovarian Cancer: Market Characterization
3.1 Ovarian Cancer Market
3.2 Ovarian Cancer Market Forecasts and CAGR
3.3 Drivers for Ovarian Cancer Market
3.3.1 High Incidence
3.3.2 High Mortality Rate
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer
3.3.4 Emergence of Targeted Drugs
3.3.5 Recurrence of Tumor
3.3.6 Low Initial Diagnosis Rate
4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer
5 Paclitaxel
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.3.1 First Line of Treatment of Advanced Ovarian Cancer
5.3.2 Second Line of Treatment of Advanced Ovarian Cancer
5.4 Approval History of Paclitaxel
5.5 Factors Affecting Sales
5.5.1 Patent Expiry of branded Paclitaxel (Taxol)
5.5.2 Increase in generic competition
5.5.3 Highest Efficacy of paclitaxel in Combination with cisplatin for the First Line Treatment
5.5.4 Better efficacy of paclitaxel in combination with Avastin for advanced ovarian cancer
5.6 Drug Evaluation
5.6.1 Drug Risk Benefit Score
5.6.2 Intensity of Competition
5.7 Sales Forecasts
5.7.1 Target Patient Pool of Paclitaxel
5.7.2 Dosing
5.7.3 Market Penetration
5.7.4 Annual Cost of Therapy
5.7.5 Sales Projections of Paclitaxel
6 Ovarian Cancer Market: Appendix
6.1 Market Definitions
6.2 List of Abbreviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.3.8 Primary Research
6.3.9 Expert Panels
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources

1.1 List of Tables
Table 1: Ovarian Cancer, Incidences and Mortality, 2008–2030
Table 2: Detailed TNM Classification
Table 3: Phase III Trial Results of Paclitaxel, First Line, Intergroup Study
Table 4: Phase III Trial Results of Paclitaxel, First Line, Gynaecological Oncology Group Study
Table 5: Phase III Trial Results of Paclitaxel, Second Line, Ovarian Cancer
Table 6: Approval of Paclitaxel by Indication
Table 7: Drug Risk Benefit Score of Paclitaxel as First Line Treatment
Table 8: Annual Cost of Therapy of Paclitaxel, 2011
Table 9: Paclitaxel, Ovarian Cancer, Global, Sales Estimates ($m), 2002–2020
Table 10: Paclitaxel, Ovarian Cancer, The US, Sales Estimates ($m), 2002–2020
Table 11: Paclitaxel, Ovarian Cancer, The UK, Sales Estimates ($m), 2002–2020
Table 12: Paclitaxel, Ovarian Cancer, France, Sales Estimates ($m), 2002–2020
Table 13: Paclitaxel, Ovarian Cancer, Germany, Sales Estimates ($m), 2002–2020
Table 14: Paclitaxel, Ovarian Cancer, Italy, Sales Estimates ($m), 2002–2020
Table 15: Paclitaxel, Ovarian Cancer, Spain, Sales Estimates ($m), 2002–2020
Table 16: Paclitaxel, Ovarian Cancer, Japan, Sales Estimates ($m), 2002–2020

1.2 List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($bn), 2010–2020
Figure 3: Ovarian Cancer, Worldwide, Incidence (million), 2008-2030
Figure 4: Oncology, Worldwide, Incidence (million), 2008-2030
Figure 5: Ovarian Cancer, Worldwide, Mortality (million), 2008-2030
Figure 6: Broad Classification of Ovarian Cancer
Figure 7: Classification of Ovarian Cancer
Figure 8: Drug Model Diagram of Paclitaxel in the US, EU and Japan
Figure 9: Paclitaxel, Ovarian Cancer, Global, Sales Estimates ($m), 2002–2020
Figure 10: Paclitaxel, Ovarian Cancer, The US, Sales Estimates ($m), 2002–2020
Figure 11: Paclitaxel, Ovarian Cancer, The UK, Sales Estimates ($m), 2002–2020
Figure 12: Paclitaxel, Ovarian Cancer, France, Sales Estimates ($m), 2002–2020
Figure 13: Paclitaxel, Ovarian Cancer, Germany, Sales Estimates ($m), 2002–2020
Figure 14: Paclitaxel, Ovarian Cancer, Italy, Sales Estimates ($m), 2002–2020
Figure 15: Paclitaxel, Ovarian Cancer, Spain, Sales Estimates ($m), 2002–2020
Figure 16: Paclitaxel, Ovarian Cancer, Japan, Sales Estimates ($m), 2002-2020
Figure 17: Paclitaxel, Ovarian Cancer, Global, Sales Distribution (%), 2015
Figure 18: Drug Model Diagram
Figure 19: Patients Approved for the Drug

Customers who bought this item also bought

• Global Ovarian Cancer Drug Pipeline Capsule - 2012 Update
• Global Ovarian Cancer Epidemiology and Patient Flow Analysis - 2012
• Global Ovarian Cancer Drug Pipeline Capsule - 2011
• Bulk Paclitaxel - Global Strategic Business Report
• Oncology Partnering Terms and Agreements
• Global Oncology Drug Pipeline Capsule – 2012
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
• Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology
• Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2012
• RNA Interference (RNAi) - Global Strategic Business Report